The adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer was carried out with third generation of AIs, such as anastrozole, exemestane and letrozole that have shown superior efficacy and generally better safety and tolerability profile compared with tamoxifen (Arimidex, 2008). This evidence concerns the gene NR4A1 and breast carcinoma.